

# Raquel Duran

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5148050/publications.pdf>

Version: 2024-02-01

30  
papers

1,605  
citations

471371

17  
h-index

454834

30  
g-index

30  
all docs

30  
docs citations

30  
times ranked

2563  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2013, 70, 727.	4.5	374
2	Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. <i>Brain</i> , 2013, 136, 392-399.	3.7	266
3	The glucocerebrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. <i>Movement Disorders</i> , 2013, 28, 232-236.	2.2	121
4	Hyposmia and cognitive impairment in Gaucher disease patients and carriers. <i>Movement Disorders</i> , 2012, 27, 526-532.	2.2	108
5	A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 853-854.	0.9	99
6	Plasma $\alpha$ -synuclein in patients with Parkinson's disease with and without treatment. <i>Movement Disorders</i> , 2010, 25, 489-493.	2.2	93
7	Genotype and phenotype in Parkinson's disease: Lessons in heterogeneity from deep brain stimulation. <i>Movement Disorders</i> , 2013, 28, 1370-1375.	2.2	77
8	Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the l-dopa. <i>Journal of the Neurological Sciences</i> , 2006, 240, 31-36.	0.3	67
9	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 460-468.	2.2	66
10	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863.	2.2	47
11	Review: Brain Aminopeptidases and Hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, 129-134.	1.0	43
12	Genome-wide assessment of Parkinson's disease in a Southern Spanish population. <i>Neurobiology of Aging</i> , 2016, 45, 213.e3-213.e9.	1.5	35
13	Oxidative stress and plasma aminopeptidase activity in Huntington's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 325-332.	1.4	29
14	Asymmetrical response of aminopeptidase A and nitric oxide in plasma of normotensive and hypertensive rats with experimental hemiparkinsonism. <i>Neuropharmacology</i> , 2009, 56, 573-579.	2.0	25
15	Analysis of the genetic variability in Parkinson's disease from Southern Spain. <i>Neurobiology of Aging</i> , 2016, 37, 210.e1-210.e5.	1.5	23
16	Stress Influences Brain Enkephalinase, Oxytocinase and Angiotensinase Activities: A New Hypothesis. <i>Neuropsychobiology</i> , 2009, 59, 184-189.	0.9	22
17	An Examination of the Mechanisms Involved in Secondary Clinical Failure to Adalimumab or Etanercept in Inflammatory Arthropathies. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 115-119.	0.5	19
18	Plasma Aminopeptidase Activities in Rats after Left and Right Intrastratial Administration of 6-Hydroxydopamine. <i>Neuroendocrinology</i> , 2004, 80, 219-224.	1.2	14

#	ARTICLE	IF	CITATIONS
19	Bilateral distribution of enkephalinase activity in the medial prefrontal cortex differs between WKY and SHR rats unilaterally lesioned with 6-hydroxydopamine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 75, 213-218.	2.5	13
20	Lateralized response of oxytocinase activity in the medial prefrontal cortex of a unilateral rat model of Parkinson's disease. <i>Behavioural Brain Research</i> , 2010, 213, 328-331.	1.2	12
21	Oxidative Stress and Aminopeptidases in Parkinson's Disease Patients with and without Treatment. <i>Neurodegenerative Diseases</i> , 2011, 8, 109-116.	0.8	12
22	Structural genomic variations and Parkinson's disease. <i>Minerva Medica</i> , 2017, 108, 438-447.	0.3	11
23	Plasma Aminopeptidase Activities in Parkinson's Disease. <i>Hormone and Metabolic Research</i> , 2006, 38, 758-760.	0.7	7
24	Asymmetrical response of aminopeptidase A in the medial prefrontal cortex and striatum of 6-OHDA-unilaterally-lesioned Wistar Kyoto and spontaneously hypertensive rats. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 182, 12-21.	1.3	6
25	Novel pathogenic mutations in the glucocerebrosidase locus. <i>Molecular Genetics and Metabolism</i> , 2012, 106, 495-497.	0.5	5
26	Aminopeptidase Activity in the Nigrostriatal System and Prefrontal Cortex of Rats with Experimental Hemiparkinsonism. <i>Hormone and Metabolic Research</i> , 2005, 37, 53-55.	0.7	4
27	Atrial Angiotensinase Activity in Hypothyroid, Euthyroid, and Hyperthyroid Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 48, 117-120.	0.8	4
28	Papel de las aminopeptidasas en el control neuroendocrino de la presión arterial en animales de experimentación. <i>Endocrinología Y Nutrición: Organo De La Sociedad Espanola De Endocrinología Y Nutrición</i> , 2008, 55, 402-408.	0.8	1
29	Asymmetric Interaction of Neuropeptidase Activities between Cortico-Limbic Structures, Plasma and Cardiovascular Function after Unilateral Dopamine Depletions of the Nigrostriatal System. <i>Biomedicines</i> , 2022, 10, 326.	1.4	1
30	Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6935.	1.8	1